Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/ki.1996.87 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reappraisal of Pidotimod: an immunomodulatory agent with 30-year evidence.
Minerva Med
August 2024
Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy -
Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4-carboxylic acid) is a synthetic dipeptide with immunomodulatory properties that is indicated for use in adults and children over 3 years of age with documented cell-mediated immunodepression during respiratory and urinary tract infections. Infections are associated with an immune response that helps fight pathogens. In this scenario, inflammatory events occur to improve the antimicrobial reaction.
View Article and Find Full Text PDFTissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis.
Cell Mol Immunol
September 2024
Department of Medicine IV, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Immune-mediated nephritis is a leading cause of acute kidney injury and chronic kidney disease. While the role of B cells and antibodies has been extensively investigated in the past, the advent of immune-checkpoint inhibitors has led to a reappraisal of the role of T cells in renal immunology. However, it remains elusive how T cells with specificity for renal autoantigens are activated and participate in immune-mediated nephritis.
View Article and Find Full Text PDFReappraisal of psoriasis pathogenesis: the role of TEAD4 expression in keratinocytes.
Int J Dermatol
November 2024
Pathology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt.
Background: Psoriasis is an immune-mediated inflammatory skin disorder with a multifaceted pathogenesis. Immune dysregulation and immune cell dysfunction are among the mechanisms involved. TEA domain family member 4 (TEAD4) is suggested to play a role in psoriasis development.
View Article and Find Full Text PDFReappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military.
Mil Med
November 2024
Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Introduction: Psoriasis and atopic dermatitis are chronic, immune-mediated skin disorders that are disqualifying for entrance into the military. Both conditions can cause difficulty wearing body armor and other protective equipment when poorly controlled, limiting a service member's ability to train and deploy worldwide. In addition, these conditions may be exacerbated by military service because of increased exposure to austere environments, extreme temperatures, stress, skin injury, bug bites, and vaccinations Service members have limited treatment options because of restrictions on systemic medications that can be used while deployed.
View Article and Find Full Text PDFMovement Disorders in Oncology: From Clinical Features to Biomarkers.
Biomedicines
December 2021
Department of Neurology, Santa Maria University Hospital, 05100 Terni, Italy.
Background: the study of movement disorders associated with oncological diseases and anticancer treatments highlights the wide range of differential diagnoses that need to be considered. In this context, the role of immune-mediated conditions is increasingly recognized and relevant, as they represent treatable disorders.
Methods: we reappraise the phenomenology, pathophysiology, diagnostic testing, and treatment of movement disorders observed in the context of brain tumors, paraneoplastic conditions, and cancer immunotherapy, such as immune-checkpoint inhibitors (ICIs).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!